Advanced search
Start date

Search for the mechanism of action and therapeutic effect of new classes of drugs against Mycobacterium tuberculosis

Grant number: 20/13497-4
Support type:Regular Research Grants
Duration: July 01, 2021 - June 30, 2023
Field of knowledge:Biological Sciences - Microbiology - Applied Microbiology
Principal researcher:Fernando Rogério Pavan
Grantee:Fernando Rogério Pavan
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Assoc. researchers: Daniele Castagnolo ; Jean Leandro dos Santos


Tuberculosis (TB) is one of the 10 leading causes of death in the world and is the disease caused by a single infectious agent with a higher mortality rate, being ahead of HIV/AIDS. Its complex and long treatment, added to the high rate of bacterial resistance, makes it one of the targets pointed out by the World Health Organization along with 12 more bacteria as determinants in the urgency in research and development (R&D) of new antimicrobials. In the last 8 years, we researched different classes of new compounds with possible properties against Mycobacterium tuberculosis and found 7 highly promising compounds, which are: synthetic compounds and benzofuroxan derivatives BZ8, TB10 and TB13, natural compounds tanshinone I, tanshinone IIA and Cryptotanshinone and the complex commercial tris- (1,10-phenanthroline)iron(II). We can divide them into 3 groups, with completely different chemical characteristics, but with high potential within a pipeline to search for new drugs against TB. Alongside these compounds, we developed, together with a group from King's College, a nanocarrier (liposome) functionalized with siderophores and moxifloxacin. At the present moment of the research, we need to understand what is the therapeutic effect of these compounds in models of BALB/c mice and understand the mechanism of action of each one through the complete genomic sequencing (SGC) of naturally resistant mutants. The results obtained in this project, added to all previous studies, will lead to the final outcome of these compounds and the possibility of a new product to be presented to the pharmaceutical industry. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
ROQUE-BORDA, CESAR AUGUSTO; DA SILVA, PATRICIA BENTO; RODRIGUES, MOSAR CORREA; AZEVEDO, RICARDO BENTES; DI FILIPPO, LEONARDO; DUARTE, JONATAS L.; CHORILLI, MARLUS; VICENTE, EDUARDO FESTOZO; PAVAN, FERNANDO ROGERIO. Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria. PHARMACEUTICS, v. 13, n. 6, . (20/16573-3, 20/13497-4, 18/25707-3)
SOLCIA, MARIANA CRISTINA; CAMPOS, DEBORA LEITE; GRECCO, JULIA ARAUJO; PAIVA SILVA, CAIO SANDER; DA SILVA, PATRICIA BENTO; DA SILVA, ISABEL CRISTIANE; BALDUINO DA SILVA, ANA PAULA; SILVA, JOAS; ODA, FERNANDO BOMBARDA; DOS SANTOS, ANDRE GONZAGA; et al. rowth-inhibitory effects of tris-(1,10-phenanthroline) iron (II) against Mycobacterium tuberculosis in vitro and in viv. TUBERCULOSIS, v. 128, . (20/13497-4, 18/12270-6, 17/12419-7, 16/24633-0, 18/21778-3, 18/12135-1, 18/00163-0)

Please report errors in scientific publications list by writing to: